Previous 10 | Next 10 |
home / stock / aplif / aplif news
Appili Therapeutics (APLIF): F1H GAAP EPS of -$0.09.Cash and short-term investments of $22.9M.Press Release For further details see: Appili Therapeutics reports F1H results
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced its financial and operational results for the second quarter of its fiscal year 2021, which ended September 30, 2020. ...
Consortium brings together world-class and globally coordinated clinical development, commercialization, cGMP manufacturing, and logistics expertise to accelerate the deployment and availability of Avigan® tablets for the potential treatment and prevention of COVID-19 A...
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company developing anti-infective drug candidates, today announced that it has recruited Don Cilla, PharmD, MBA, to serve as the Company’s new Chief Dev...
Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, announced today that Appili’s CEO Dr. Armand Balboni will be presenting at the first-ever Life Sc...
Appili Therapeutics ([[APLIF]]) has entered into an agreement with Ology Biosciences, under which Ology will manufacture ATI-1701, a novel live attenuated tularemia vaccine candidate.The U.S. Department of Defense has awarded Ology Bioservices $6.3M for ATI-1701 manufacturing and development ...
Agreement with Ology Bioservices and a $6.3MM DTRA contract enable next stage of manufacturing and development for world’s first vaccine to prevent F. tularensis , a potential biological weapons threat Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Compan...
The first participants have been dosed in a Phase 2 clinical trial evaluating Appili Therapeutics' (APLIF) favipiravir as a preventative measure against COVID-19 outbreaks in long-term care ((LTC)) facilities.The trial will include elderly subjects with comorbidities at 16 LTC centers and fro...
CONTROL trial is part of Appili’s unique approach to evaluating favipiravir in early-stage disease in the community setting for those most vulnerable to COVID-19, including the elderly, those with significant comorbidities, and frontline workers Researchers plan to enro...
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Wednesday, Septem...
News, Short Squeeze, Breakout and More Instantly...
Appili Therapeutics Inc Company Name:
APLIF Stock Symbol:
OTCMKTS Market:
Appili Therapeutics Inc Website:
Appili, with a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets. Subject to the renewal of certain legislation, two programs are potentially eligible for FDA Priority Review Vouchers Aditxt, Inc. (...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmace...